Sunday, 22 July 2018 - 17:27
  • it
  • de
  • en
  • fr


Deborah Dunsire named new CEO of Lundbeck

The Board of Directors of Danish pharmaceutical company Lundbeck appointed Dr. Deborah Dunsire as its new CEO today. She will take up her new position on 1 September 2018, taking over from CEO Kare Schultz, who left to become Teva’s…

Lundbeck to pursue M&A again soon

Denmark-based Lundbeck may soon sign a new acquisition agreement, after taking over Prexton Therapeutics two months ago for $905m. The group is apparently targeting companies with candidates still undergoing the early stages of clinical trials, intended to treat central nervous…

Lundbeck acquires Netherlands-based Prexton Therapeutics for €955m

Denmark-based Lundbeck A/S has announced today it has acquired Netherlands-based Prexton Therapeutics BV for €955m. Specifically, the agreement includes an upfront €100m payment, plus an additional €805m if Prexton reaches precise commercial targets. Prexton’s main asset is probably foliglurax, a…